Ginkgo Biloba and Ocular Blood Flow in Primary Open-angle Glaucoma

• ClinicalTrials.gov Identifier: NCT02376114
• Recruitment Status: Completed
• First Posted: March 3, 2015
• Last Update Posted: March 3, 2015
• Sponsor: Maisonneuve-Rosemont Hospital
• Information provided by (Responsible Party): Ellen Freeman, Maisonneuve-Rosemont Hospital

Study Description

Brief Summary:

Glaucoma is one of the leading causes of blindness. Ginkgo biloba may be part of an effective treatment strategy for glaucoma because it has been shown to improve blood flow, it has antioxidant properties, it can relax smooth muscle, and it can protect neurons from damage. The goal of our study was to determine whether Ginkgo biloba would result in increased ocular blood flow which may protect against glaucoma damage.

Condition or disease	Intervention/treatment	Phase
Glaucoma, Open-Angle	Drug: Ginkgo biloba; Drug: Placebo to Ginkgo biloba	Phase 2

Detailed Description:

Glaucoma is one of the leading causes of blindness. Glaucoma progression sometimes occurs despite apparent control of intraocular pressure. Therefore, there may be other factors involved in glaucoma progression in some patients. Evidence is mounting that glaucoma patients are more likely to have abnormal ocular blood flow and vasospasm compared to those without glaucoma. Also, a study showed that those with progressive glaucoma had decreased blood flow compared to those with stable glaucoma or healthy controls. Endothelin-1, a potent vasoconstrictor, may be involved in these blood flow abnormalities. If the dysregulation of blood flow is causally related to the progression of glaucoma, then therapies aimed at improving the regulation of blood flow may help to prevent this progression.

Ginkgo may be part of an effective treatment strategy for glaucoma because it has been shown to improve peripheral and cerebral blood flow. Other properties of Ginkgo that may aid in the treatment of glaucoma include antioxidant properties, inhibition of platelet activating factor, relaxation of smooth muscle, and neuroprotective properties. Ginkgo may be particularly useful in relaxing vasospasm. Two controlled trials have examined the effect of Ginkgo on ocular blood flow in healthy subjects. One randomized crossover trial found that 2 days of Ginkgo increased the end diastolic velocity in the ophthalmic artery compared to placebo. However, another trial found that 1 dose of Ginkgo had no significant effects on ocular blood flow parameters. In people with normal tension glaucoma, Park et al found that 4 weeks of Ginkgo increased peripapillary retinal blood flow. Two randomized controlled trials have examined the impact of Ginkgo biloba on visual field in people with normal tension glaucoma with conflicting results. Clearly, there is a need for more research on this topic.

The goal of our study was to determine whether Ginkgo biloba would result in increased ocular blood flow, reduced vasospasm, and reduced endothelin-1 levels.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 19 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: Double (Participant, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: The Effect of Ginkgo Biloba on Ocular Blood Flow in Primary Open-Angle Glaucoma Patients: A Double-Blind Randomized Crossover Trial
• Study Start Date: August 2011
• Actual Primary Completion Date: February 2014
• Actual Study Completion Date: February 2014

Arms and Interventions

Arm	Intervention/treatment
Ginkgo-Placebo; Patients receive Ginkgo biloba and then placebo afterwards.	Drug: Ginkgo biloba; The Ginkgo biloba extract that was used contained 24% ginkgo flavone glycosides and 6% terpene lactones (Vitamin Research Products, Carson City, Nevada). Patients took 60 mg of Ginkgo or a placebo twice daily by mouth for two weeks. The placebo consisted of 40 mg of corn starch. Ginkgo and the placebo were encapsulated to ensure identical appearance.
Placebo-Ginkgo; Patients receive placebo and then Ginkgo biloba afterwards.	Drug: Placebo to Ginkgo biloba

Outcome Measures

Primary Outcome Measures :

1. Change in optic nerve head blood flow in the rim region as measured with the Heidelberg Retinal Flowmeter [ Time Frame: 4 weeks and 10 weeks ]
   Change in optic nerve head blood flow in the rim region as measured with the Heidelberg Retinal Flowmeter

Secondary Outcome Measures :

1. Change in retinal blood flow as measured by the Canon Laser Blood Flowmeter [ Time Frame: 4 weeks and 10 weeks ]
   Change in retinal blood flow as measured by the Canon Laser Blood Flowmeter
2. Change in ocular pulse amplitude as measured with the Pascal Dynamic Contour Tonometer [ Time Frame: 4 weeks and 10 weeks ]
   Change in ocular pulse amplitude as measured with the Pascal Dynamic Contour Tonometer
3. Change in peripheral vasospasm as measured during the cold provocation test using the Transonic Laser Doppler Flowmeter [ Time Frame: 4 weeks and 10 weeks ]
   Change in peripheral vasospasm as measured during the cold provocation test as measured using the Transonic Laser Doppler Flowmeter
4. Change in endothelin-1 levels as measured by an enzyme-linked immunosorbent assay kit [ Time Frame: 4 weeks and 10 weeks ]
   Change in endothelin-1 levels as measured by an enzyme-linked immunosorbent assay kit

Eligibility Criteria

• Ages Eligible for Study: 40 Years to 80 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• We focused this trial on vasospastic glaucoma patients because we believed that these would be the patients most likely to benefit from the ability of Ginkgo to improve blood flow.
• Patients who had been identified from previous research as being vasospastic on the Transonic Laser Doppler Flowmeter (Transonic Systems Inc., Ithaca, NY) were contacted and asked if they would like to participate in the trial.
• We recruited vasospastic patients with early or moderate primary open-angle glaucoma with a typical visual field defect with an abnormal Glaucoma Hemifield Test and a Mean Deviation worse than -2 decibels, and an optic nerve head showing retinal nerve fiber layer or neuroretinal rim loss characteristic of glaucoma.
• There was no restriction for intraocular pressure at time of diagnosis although at the time of recruitment intraocular pressure had to be effectively controlled either by ocular hypertension therapy or by surgery.
• If a patient had two eyes eligible, data from the right eye only was used.

Exclusion Criteria:

• those taking anticoagulant therapy,
• those with blood disorders or diabetes,
• women who were pregnant, planning to become pregnant, or who were breast-feeding,
• patients with a history of seizures or who were currently taking anti-convulsant medication, and
• those who could not return for 2 follow-up visits at 4 and 6 weeks.
• those patients who are already taking Ginkgo were asked if they were willing to stop for 6 weeks before the study.

Contacts and Locations

Locations

Canada, Quebec

Maisonneuve-Rosemont Hospital

Montreal, Quebec, Canada, H1T2M4

Sponsors and Collaborators

Maisonneuve-Rosemont Hospital

Investigators

• Principal Investigator: Ellen Freeman, PhD; Maisonneuve-Rosemont Hospital
• Principal Investigator: Mark Lesk, MD; Maisonneuve-Rosemont Hospital

More Information

• Responsible Party: Ellen Freeman, Associate Professor, Maisonneuve-Rosemont Hospital
• ClinicalTrials.gov Identifier: NCT02376114
• Other Study ID Numbers: Ginkgo and blood flow
• First Posted: March 3, 2015
• Last Update Posted: March 3, 2015
• Last Verified: February 2015

Keywords provided by Ellen Freeman, Maisonneuve-Rosemont Hospital:

ocular blood flow; ginkgo biloba; glaucoma; vasospasm

Additional relevant MeSH terms:

Glaucoma; Glaucoma, Open-Angle; Ocular Hypertension; Eye Diseases